Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non–small Cell Lung Cancer With a PD-L1 Expression ≥50% or ≥90%

Mohsin Shah, Ronac Mamtani, Melina E. Marmarelis, Sean Hennessy